Antares Pharma (ATRS) is being set up to run to at least $3.85, Thesis follows below; The chart above shows “quiet” accumulation. The purple line is the accumulation, notice for the first time, the accumulation points up, MACD and RSI…
Tag: stock
Significant catalysts and an unfortunate PR mistake present an opportunity in AcelRx Pharmaceuticals.
With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
AcelRx Pharma Selloff Caused By Error In Recent Press Release
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
Why the latest rally could be a bull trap
This week has been a strange market week for sure. I have held back on picks mainly because I want to see some clarity as I believe we are at a market top, and economic data has peaked out. Furthermore,…
GLOBE NEWSWIRE: Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
UPDATED: Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
DARA Poised to Break Out on Catalysts
DARA Biosciences (NASDAQ: DARA) is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration (FDA) in November of last year for its drug KRN5500, which is being studied for the…
4 Small Cap Biopharmas With Near-Term Catalysts
To begin this week, I list four biopharma companies I feel have significant catalysts coming up. According to investinganswers.com a catalyst is defined as news or information that changes a pricing trend in a security. Catalysts can drive an investment…
The Obesity Epidemic – EnteroMedics New Treatment Approach
Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
UPDATED: EnteroMedics (ETRM) Basic DD and Thesis
EnteroMedics Inc. (ETRM) I bought a nice amount of shares. Catalyst trade run up target opinion: $.4.40. Positive data release: Gap to $7. 1 year: $15 (my opinions only) According to company press releases, conference calls, and my correspondence with…
